Received May 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMV8072A | — |
product complaint; expired drug used; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 17-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMV8072A, expiry date 30-APR-2026) for prophylaxis. This case was associated with a product complaint. On 19-MAY-2026, the patient received Menveo. On 19-MAY-2026, an unknown time after receiving Menveo, the patient experienced expired vaccine used (Verbatim: expired drug used). On an unknown date, the patient experienced pharmaceutical product complaint (Verbatim: product complaint). The outcome of the expired vaccine used and pharmaceutical product complaint were not applicable. Additional Information: GSK Receipt Date: 20-MAY-2026 The medical assistant reported that a Menveo two vial presentation had been administered to a patient. The expiration dates were as follows the powder portion 30-APR-2026, the liquid conjugate 31-DEC-2026 and the packaging 31-MAY-2026. The powder portion had expired prior to administration. The vaccine administration facility was the same as the primary reporter. The reporter reporting because one expiration date had passed prior to admin - a product quality complaint was filed also just in case.